An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Lunsekimig (Primary)
- Indications Asthma
- Focus Adverse reactions
- Acronyms AIRPHRODITE
- Sponsors Sanofi
- 30 Sep 2024 New trial record